Haematology
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      1L CLL

      R/R CLL

      AML

      RESOURCE HUB

      CONTACT

      VENCLEXTA logo
      #

      The CLL 14 trial was a multicentre, open-label, phase 3 study that evaluated fixed-duration treatment with VENCLEXTA plus obinutuzumab versus chlorambucil plus obinutuzumab, in patients with previously untreated CLL and coexisting medical conditions.1,3 

      Key efficacy and safety findings in the
      5-year update of the CLL14 trial

      What the 5-year update of the CLL14 trial means for Australian Haematologists and their patients

      Advice for Haematologists who have yet to initiate VENCLEXTA in patients with
      1L CLL

      Clinical Perspectives on the CLL14 Trial in 1L CLL1

      Barbara Eichhorst deep dive

      Contact

      Discover more about how we can help you in your practice.

      Contact Now

      PBS Information

      Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.

      Please review the full Product Information (PI) before prescribing, available below.

      Venclexta PI

      References: 1. Fischer K et al. N Engl J Med 2019; 380: 2225–36. 2. Al-Sawaf O et al. Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. Abstract presented at the European Hematology Association (EHA) Hybrid Congress 2022. 3. VENCLEXTA Product Information.

      AU-VENC-210039 September 2022